{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-065988","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.696690+00:00","generated_at":"2026-06-14T11:07:36.329457+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Rigel shareholders approve equity plan amendment adding 4M shares, elect directors","bullets":["Stockholders approved amendment to 2018 Equity Incentive Plan, increasing authorized shares by 4,000,000.","Three directors elected: Alison L. Hannah, Walter H. Moos, Raul R. Rodriguez.","Advisory say-on-pay approved with 76.6 million votes for.","Board determined to hold annual advisory vote on executive compensation.","Ratification of Ernst & Young as independent auditor for fiscal 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-065988","json":"https://secwatch.observer/filing/0001104659-23-065988.json","markdown":"https://secwatch.observer/filing/0001104659-23-065988.md","text":"https://secwatch.observer/filing/0001104659-23-065988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923065988/0001104659-23-065988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923065988/tm2317252d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:07:36.329457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2054625b3db1953773b3badf49fa589eb745c18f","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Say-on-Frequency.","evidence_excerpt":"Say-on-Frequency The Company's stockholders approved, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers as disclosed in the Proxy Statement. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 82,264,431 168,884 1,905,936 11,738,369 36,301,619","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923065988/0001104659-23-065988-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"485cc319909818ebe9da3bf1b9ff6a26cd83dd03","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Ratification of Selection of Ernst & Young at the 2023-12-31 meeting.","evidence_excerpt":"Ratification of Selection of Ernst & Young The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. For Against Abstain Broker Non-Votes 119,779,873 2,561,946 10,037,420 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923065988/0001104659-23-065988-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"673127d782a4975b6e81c86aa175773fd01abaa8","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Say-on-Pay.","evidence_excerpt":"Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. For Against Abstain Broker Non-Votes 76,640,368 7,558,152 11,879,100 36,301,619","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923065988/0001104659-23-065988-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"8e11a2ea9cac67cc9007c69653bebf39539ce110","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Election of Directors.","evidence_excerpt":"Election of Directors Each of the three nominees for director, to serve until the Company's 2026 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows: Name of Director For Withheld Broker Non-Votes Alison L. Hannah 75,693,596 20,384,024 36,301,619 Walter H. Moos 79,771,626 16,305,994 36,301,619 Raul R. Rodriguez 80,052,247 16,025,373 36,301,619","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923065988/0001104659-23-065988-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"9ff43774eef7a698027b7df39e3e17695dadf693","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Approval of the Amended 2018 Plan.","evidence_excerpt":"Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan. For Against Abstain Broker Non-Votes 56,561,234 30,007,992 9,508,394 36,301,619","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923065988/0001104659-23-065988-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}